One cell.One adaptor.Multiple targets.
We are developing a novel switchable CAR-T/NK cell platform for the treatment of cancer and autoimmune disorders.
01 — About us
The future of cell therapy is Programmable.
We are SNAP Bio, a wholly-owned subsidiary of Coeptis Holdings, Inc.
Our switchable CAR-T/NK platform is designed to overcome major limitations of conventional “hard-wired” CAR designs, as well as outperform the new class of “switchable” CAR prototypes.
Get in touch02 — Our Science
One adaptor. Multiple antigens.
Switching the adaptor to switch the target isn’t new. What is: a single adaptor that engages two or more antigens at once. One cell, one adaptor, multiple targets.
Conventional CAR
Hard-wired to one target
The receptor is fixed to a single antigen — maybe two. Every new target means re-engineering the whole cell.
Other switchable CARs
Swappable, still single-target
Change the adaptor to change the target — but each adaptor still binds just one antigen at a time.
SNAP-CAR
Switchable and multi-antigen
A single adaptor engages two or more antigens at once. Switch the adaptor, switch the target — and hit several together.
03 — Our chemistry
Why “SNAP” is better.
A switchable CAR grips its adaptor with affinity on both sides — a bond that is always half-letting-go. Receptor signaling stutters, so the target has to be densely expressed for the cell to stay engaged.
SNAP-CAR welds the adaptor on with a covalent bond — the receptor and adaptor become one piece. Signaling holds, and the cell stays lethal even against low-abundance targets.
04 — Our Roadmap
Platform licensing & integration
The universal SNAP-CAR adaptor platform is licensed and integrated. One manufactured T- or NK-cell product, redirected by swappable adaptors across liquid and solid tumors.
Preclinical platform optimization
IND-enabling optimization of the platform, establishing preclinical efficacy and proof of concept ahead of the clinic.
IND submission
Filing the Investigational New Drug application. A successful submission clears SNAP-CAR into first-in-human study.
First patient dosed
The Phase 1 trial opens and the first patient is dosed with a SNAP-CAR product.
Dose escalation & platform expansion
Dose escalation with safety and PK/PD assessment, generating preliminary efficacy and biomarker data, while expanding the platform to new targets and indications.
Team
Experienced leaders.
Deep expertise in oncology drug and cell therapy development, business strategy, and operational excellence.
Co-Founder, President & CEO
30 years across healthcare, IT, finance, and capital markets leadership.
Co-Founder & VP of Operations
10+ years spanning pharmaceutical operations, supply chain, and business development.
VP of Compliance & Corporate Secretary
30 years leading finance, operations, and global systems for life sciences.
Partner with us to make cell therapy programmable.
We’re always looking to connect with collaborators, investors, and future team members.